IP Library Granted Patent US 11,547,704
Granted Patent B2
US 11,547,704 · App. 16/898,667 · Granted Jan 10, 2023

Chemical compounds

Inventors: Jeffrey Michael Axten (Collegeville, PA); Mui Cheung (Collegeville, PA); Michael P. Demartino (Collegeville, PA); Hilary Schenck Eidam (Collegeville, PA); Raghava Reddy Kethiri (Subramanyapura, IN); Biswajit Kalita (Bangalore, IN)
Assignee: GlaxoSmithKline Intellectual Property Development Limited
A61K31/4468A61K31/438A61K31/439A61K31/445A61K31/454C07D209/52C07D211/26C07D211/32C07D211/56C07D211/58C07D211/60C07D211/62C07D211/66C07D401/04C07D401/12C07D403/12C07D405/12C07D417/12C07D451/04C07D471/08C07D498/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,547,704
App. No.
16/898,667
Granted
Jan 10, 2023
Kind
B2
Abstract

The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L 1 , L 2 , L 3 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , z 2 , z 4 , z 5 , and z 6 are as defined herein, and salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Claims (7)

1. A compound which is

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical combination comprising:

a) a compound as described in claim 1 or a pharmaceutically acceptable salt thereof; and

b) at least one anti-neoplastic agent.

3. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

4. The compound of claim 1 which is a hydrochloride salt thereof.

Assignments (2)
CHANGE OF ADDRESS Recorded Oct 8, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 073032/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2020
From: AXTEN, JEFFREY MICHAEL; CHEUNG, MUI; DEMARTINO, MICHAEL P.; EIDAM, HILARY SCHENCK; KETHIRI, RAGHAVA REDDY; KALITA, BISWAJIT
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 052907/0004 →
Priority Claims (1)
IN 201611019716 · Jun 8, 2016 · national
Continuity (2)
Continuation 16307507
Related Publication 20200297710A1 · Sep 24, 2020
Cited By (1)
US 12,258,338